AstraZeneca
Genecast to Evaluate Liquid Biopsy EGFR Mutation Test in Early-Stage Non-Small Cell Lung Cancer
The firm hopes its qPCR-based liquid biopsy test could help identify early-stage NSCLC patients eligible for adjuvant or neoadjuvant anti-EGFR TKI treatment.
Lynparza Benefit in Early BRCA-Mutated Breast Cancer Reignites Universal Genetic Testing Discussion
Premium
The OlympiA trial showed a disease-free survival benefit with adjuvant PARP inhibitor therapy for early-stage, BRCA1/2-mutated, HER2-negative breast cancer patients.
Akoya Biosciences, AstraZeneca Collaborate on Spatial Biomarker Profiling for Immuno-Oncology
The firms will study drug mechanisms of action, confirm the prevalence of targets, and discover predictive signatures for subsequent trial designs.
Adaptive Cofounder and Chief Scientific Officer Harlan Robins compared the launch of the test to the unveiling of the Tesla Roadster electric sports car.
AmoyDx, AstraZeneca Strike Ovarian Cancer Companion Diagnostic Alliance
The companies have worked together on a number of other cancer-related projects, including a companion diagnostic for the ovarian cancer treatment olaparib.